Upregulation of GSK3β expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci)

Brain Research

Volumn 1196, Issue , 2008, Pages 131-139

  Yang, Wencheng ^a   Leystra Lantz, Cheryl ^a   Strong, Michael J ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Amyotrophic lateral sclerosis (ALS); Frontotemporal dementia; GSK3 ; Microtubule associated tau protein; Protein kinase

Indexed keywords

BETA ACTIN; BETA CATENIN; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN P25; PROTEIN P35; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TEMPORAL CORTEX; UPREGULATION; WESTERN BLOTTING; ANALYSIS OF VARIANCE; CADAVER; ENZYMOLOGY; FRONTAL LOBE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TEMPORAL LOBE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANALYSIS OF VARIANCE; BETA CATENIN; COGNITION DISORDERS; FEMALE; FRONTAL LOBE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MIDDLE AGED; POSTMORTEM CHANGES; TEMPORAL LOBE; UP-REGULATION;

EID: 39149141844     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.12.031     Document Type: Article

References (45)

1. Bajaj N.P. Cyclin-dependent kinase-5 (CDK5) and amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1 (2000) 319-327
2. Balaraman Y., Limaye A.R., Levey A.I., and Srinivasan S. Glycogen synthase kinase 3β and Alzheimer's disease: pathophysiological and therapeutic significance. Cell. Mol. Life Sci. 63 (2006) 1226-1235
3. Brooks B.R., Miller R.G., Swash M., and Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1 (2000) 293-299
4. Camins A., Verdaguer E., Folch J., Canudas A.M., and Pallas M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect. 19 (2006) 453-460
5. Cheung Z.H., and Ip N.Y. Cdk5: mediator of neuronal death and survival. Neurosci. Lett. 361 (2004) 47-51
6. Cook D., Fry M.J., Hughes K., Sumathipala R., Woodgett J.R., and Dale T.C. Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a protein kinase C. EMBO J. 15 (1996) 4526-4536
7. Ferrer I., Gomez-Isla T., Puig B., Freixes M., Ribe E., Dalfo E., and Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr. Alzheimer Res. 2 (2005) 3-18
8. Frame S., and Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359 (2001) 1-16
9. Giese K.P., Ris L., and Plattner F. Is there a role of the cyclin-dependent kinase 5 activator p25 in Alzheimer's disease?. Neuroreport 16 (2005) 1725-1730
10. Grimes C.A., and Jope R.S. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog. Neurobiol. 65 (2001) 391-426
11. Hanger D.P., Hughes K., Woodgett J.R., Brion J.P., and Anderton B.H. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147 (1992) 58-62
12. Hisanaga S., and Saito T. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. Neurosignals 12 (2003) 221-229
13. Hughes K., Nikolakaki E., Plyte S.E., Totty N.F., and Woodgett J.R. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 12 (1993) 803-808
14. Ishiguro K., Omori A., Takamatsu M., Sato K., Arioka M., Uchida T., and Imahori K. Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci. Lett. 148 (1992) 202-206
15. Ishiguro K., Takamatsu M., Tomizawa K., Omori A., Takahashi M., Arioka M., Uchida T., and Imahori K. Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments. J. Biol. Chem. 267 (1992) 10897-10901
16. Itoh N., Ishiguro K., Arai H., Kokubo Y., Sasaki R., Narita Y., and Kuzuhara S. Biochemical and ultrastructural study of neurofibrillary tangles in amyotrophic lateral sclerosis/parkinsonism-dementia complex in the Kii peninsula of Japan. J. Neuropathol. Exp. Neurol. 62 (2003) 791-798
17. Koh S.H., Lee Y.B., Kim K.S., Kim H.J., Kim M., Lee Y.J., Kim J., Lee K.W., and Kim S.H. Role of GSK-3β activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene. Eur. J. Neurosci. 22 (2005) 301-309
18. Koh S.H., Kim Y., Kim H.Y., Hwang S., Lee C.H., and Kim S.H. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp. Neurol. 205 (2007) 336-346
19. Kosik K.S., and Shimura H. Phosphorylated tau and the neurodegenerative foldopathies. Biochim. Biophys. Acta 1739 (2005) 298-310
20. Leroy K., and Brion J.P. Developmental expression and localization of glycogen synthase kinase-3β in rat brain. J. Chem. Neuroanat. 16 (1999) 279-293
21. Leroy K., Boutajangout A., Authelet M., Woodgett J.R., Anderton B.H., and Brion J.P. The active form of glycogen synthase kinase-3β is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol. (Berl) 103 (2002) 91-99
22. Lim A.C., and Qi R.Z. Cyclin-dependent kinases in neural development and degeneration. J. Alzheimers Dis. 5 (2003) 329-335
23. Mandelkow E.M., Drewes G., Biernat J., Gustke N., Van L.J., Vandenheede J.R., and Mandelkow E. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett. 314 (1992) 315-321
24. Morfini G., Szebenyi G., Brown H., Pant H.C., Pigino G., DeBoer S., Beffert U., and Brady S.T. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J. 23 (2004) 2235-2245
25. Mukai F., Ishiguro K., Sano Y., and Fujita S.C. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β. J. Neurochem. 81 (2002) 1073-1083
26. Nguyen M.D., Lariviere R.C., and Julien J.P. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 30 (2001) 135-147
27. Patrick G.N., Zukerberg L., Nikolic M., de la M.S., Dikkes P., and Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402 (1999) 615-622
28. Patzke H., and Tsai L.H. Cdk5 sinks into ALS. Trends Neurosci. 25 (2002) 8-10
29. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., and Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56 (1997) 70-78
30. Plattner F., Angelo M., and Giese K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 281 (2006) 25457-25465
31. Puig B., Vinals F., and Ferrer I. Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick's disease. Acta Neuropathol. (Berl) 107 (2004) 185-189
32. Rubinfeld B., Albert I., Porfiri E., Fiol C., Munemitsu S., and Polakis P. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science 272 (1996) 1023-1026
33. Shelton S.B., and Johnson G.V. Cyclin-dependent kinase-5 in neurodegeneration. J. Neurochem. 88 (2004) 1313-1326
34. Spittaels K., Van den H.C., Van D.J., Geerts H., Mercken M., Bruynseels K., Lasrado R., Vandezande K., Laenen I., Boon T., Van L.J., Vandenheede J., Moechars D., Loos R., and Van L.F. Glycogen synthase kinase-3β phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 275 (2000) 41340-41349
35. Strong M.J., Yang W., Strong W.L., Leystra-Lantz C., Jaffe H., and Pant H.C. Tau protein hyperphosphorylation in sporadic ALS with cognitive impairment. Neurology 66 (2006) 1770-1771
36. Takahashi S., and Kulkarni A.B. Mutant superoxide dismutase 1 causes motor neuron degeneration independent of cyclin-dependent kinase 5 activation by p35 or p25. J. Neurochem. 88 (2004) 1295-1304
37. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J. Alzheimers Dis. 9 (2006) 309-317
38. Wakayama I., Kihira T., Yoshida S., and Garruto R.M. Rare neuropil threads in amyotrophic lateral sclerosis and parkinsonism-dementia on Guam and in the Kii Peninsula of Japan. Dementia 4 (1993) 75-80
39. Weishaupt J.H., Neusch C., and Bahr M. Cyclin-dependent kinase 5 (CDK5) and neuronal cell death. Cell Tissue Res. 312 (2003) 1-8
40. Wilson C.M., Grace G.M., Munoz D.G., He B.P., and Strong M.J. Cognitive impairment in sporadic ALS: a pathologic continuum underlying a multisystem disorder. Neurology 57 (2001) 651-657
41. Yang W., Sopper M.M., Leystra-Lantz C., and Strong M.J. Microtubule-associated tau protein positive neuronal and glial inclusions in ALS. Neurology 61 (2003) 1766-1773
42. Yang W., Ang L.C., and Strong M.J. Tau protein aggregation in the frontal and entorhinal cortices as a function of aging. Brain Res. Dev. Brain Res. 156 (2005) 127-138
43. Yokota O., Tsuchiya K., Oda T., Ishihara T., de S.R., Lees A.J., Arai T., Uchihara T., Ishizu H., Kuroda S., and Akiyama H. Amyotrophic lateral sclerosis with dementia: an autopsy case showing many Bunina bodies, tau-positive neuronal and astrocytic plaque-like pathologies, and pallido-nigral degeneration. Acta Neuropathol. (Berl) 112 (2006) 633-645
44. Yost C., Farr III G.H., Pierce S.B., Ferkey D.M., Chen M.M., and Kimelman D. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell 93 (1998) 1031-1041
45. Zheng Y.L., Kesavapany S., Gravell M., Hamilton R.S., Schubert M., Amin N., Albers W., Grant P., and Pant H.C. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J. 24 (2005) 209-220